ISENTRESS® 400 mg (raltegravir)
ISENTRESS® 600 mg (raltegravir)
This website contains product information and resources intended only for UK Healthcare Professionals. General information about raltegravir is provided in the sections for members of the public and patients.
Reporting side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects, you can help provide more information on the safety of this medicine.
ISENTRESS 400 mg
Great Britain:
Summary of Product Characteristics | Patient Information Leaflet
Northern Ireland:
Summary of Product Characteristics | Patient Information Leaflet
ISENTRESS 600 mg
Great Britain:
Summary of Product Characteristics | Patient Information Leaflet
Northern Ireland:
Summary of Product Characteristics | Patient Information Leaflet
To contact us please telephone 0208 154 8000 or email medicalinformationuk@msd.com
GB-MFA-00200 | Date of Preparation: August 2022
Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 233687 Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000)